AI Age Discrepancy: A Novel Parameter for Frailty Assessment in Kidney Tumor Patients

TL;DR

This study introduces AI Age Discrepancy, a new machine learning-based metric from CT scans, to assess frailty and predict postoperative risks in kidney tumor patients, potentially improving clinical decision-making.

Contribution

The paper presents a novel AI-derived metric, AI Age Discrepancy, for frailty assessment in kidney cancer patients, validated through retrospective analysis of a large dataset.

Findings

Higher AI Age Discrepancy correlates with longer hospital stays.

Higher AI Age Discrepancy associates with lower overall survival.

AI Age Discrepancy provides independent predictive value.

Abstract

Kidney cancer is a global health concern, and accurate assessment of patient frailty is crucial for optimizing surgical outcomes. This paper introduces AI Age Discrepancy, a novel metric derived from machine learning analysis of preoperative abdominal CT scans, as a potential indicator of frailty and postoperative risk in kidney cancer patients. This retrospective study of 599 patients from the 2023 Kidney Tumor Segmentation (KiTS) challenge dataset found that a higher AI Age Discrepancy is significantly associated with longer hospital stays and lower overall survival rates, independent of established factors. This suggests that AI Age Discrepancy may provide valuable insights into patient frailty and could thus inform clinical decision-making in kidney cancer treatment.